Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Stukaite-Ruibiene, E; Norvilas, R; Dirse, V; Stankeviciene, S; Vaitkeviciene, GE

Stukaite-Ruibiene, E (通讯作者),Vilnius Univ, Fac Med, Vilnius, Lithuania.

PATHOLOGY & ONCOLOGY RESEARCH, 2022; 28 ():

Abstract

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, howev......

Full Text Link